Part of the tumor-protective effect has been attributed to the gain of a third copy of the Down syndrome critical region-1 (Dscr1) gene, a calcineurin inhibitor that acts as a suppressor of VEGF-mediated angiogenic signaling [98]. Here, RCAN1 is linked to neoplasm.